Literature DB >> 23143897

10-Fold increase (2006-11) in the rate of healthy subjects with extended-spectrum β-lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre.

Marie-Hélène Nicolas-Chanoine1, Coraline Gruson, Suzanne Bialek-Davenet, Xavier Bertrand, Frédérique Thomas-Jean, Frédéric Bert, Mati Moyat, Elodie Meiller, Estelle Marcon, Nicolas Danchin, Latifa Noussair, Richard Moreau, Véronique Leflon-Guibout.   

Abstract

OBJECTIVES: In 2006, 0.6% of healthy subjects living in the Paris area had extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in their gut. To assess the evolution of this rate, a study identical to that of 2006 was conducted in 2011. PARTICIPANTS AND METHODS: Healthy adults who visited the IPC check-up centre in February-March 2011 and agreed to participate, provided stools and answered a questionnaire on the visit day. Stools were analysed to detect ESBL producers and to isolate the dominant E. coli population. ESBLs were molecularly characterized. For the subjects harbouring ESBL-producing E. coli, the phylogenetic group and sequence type (ST) were determined for both ESBL-producing and dominant E. coli isolates. PFGE profiles were also determined when two types of isolates had the same ST.
RESULTS: Among the 345 subjects included, 21 (6%) had ESBL-producing E. coli faecal carriage. None of the previously published risk factors was identified. CTX-M accounted for 86% and SHV-12 for 14%. Dominant and ESBL-producing E. coli were similarly distributed into phylogenetic groups (A, 52%-48%; B1, 5%; B2, 24%-14%; and D, 19%-33%). Dominant and ESBL-producing E. coli displayed a polyclonal structure (18 STs each). However, ST10 and ST131 were identified in dominant and ESBL-producing E. coli isolates from different subjects. Most (20/21) ESBL producers were subdominant and belonged (16/21) to STs different from that of the corresponding dominant E. coli.
CONCLUSIONS: The 10-fold increase in the rate of healthy subjects with ESBL-producing E. coli faecal carriage over a 5 year period suggests wide dissemination of these isolates in the Parisian community.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143897     DOI: 10.1093/jac/dks429

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  48 in total

1.  High prevalence of blaCTX-M-1/IncI1/ST3 and blaCMY-2/IncI1/ST2 plasmids in healthy urban dogs in France.

Authors:  Marisa Haenni; Estelle Saras; Véronique Métayer; Christine Médaille; Jean-Yves Madec
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

Review 2.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  High prevalence of the animal-associated bla CTX-M-1 IncI1/ST3 plasmid in human Escherichia coli isolates.

Authors:  Jean-Yves Madec; Marisa Haenni; Véronique Métayer; Estelle Saras; Marie-Hélène Nicolas-Chanoine
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

4.  Application of guidelines for aminoglycosides use in French hospitals in 2013-2014.

Authors:  J Robert; Y Péan; S Alfandari; J-P Bru; J-P Bedos; C Rabaud; R Gauzit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-09       Impact factor: 3.267

5.  Rapid detection of extended-spectrum-β-lactamase-producing enterobacteriaceae from urine samples by use of the ESBL NDP test.

Authors:  Laurent Dortet; Laurent Poirel; Patrice Nordmann
Journal:  J Clin Microbiol       Date:  2014-08-06       Impact factor: 5.948

6.  Prospective Cohort Study of the Relative Abundance of Extended-Spectrum-Beta-Lactamase-Producing Escherichia coli in the Gut of Patients Admitted to Hospitals.

Authors:  Victoire de Lastours; Dorothée Chopin; Hervé Jacquier; Camille d'Humières; Charles Burdet; Françoise Chau; Erick Denamur; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

7.  National prevalence of resistance to third-generation cephalosporins in Escherichia coli isolates from layer flocks in France.

Authors:  Claire Chauvin; Laetitia Le Devendec; Eric Jouy; Maena Le Cornec; Sylvie Francart; Corinne Marois-Créhan; Isabelle Kempf
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

Review 8.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  Clinical and microbiological determinants of severe and fatal outcomes in patients infected with Enterobacteriaceae producing extended-spectrum β-lactamase.

Authors:  L Surgers; A Boyd; P-Y Boelle; V Lalande; P-A Jolivot; P-M Girard; G Arlet; C Cambier; A Homor; D Decre; J-L Meynard
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-08       Impact factor: 3.267

10.  Extended-spectrum-β-lactamase-producing Escherichia coli as intestinal colonizers in the German community.

Authors:  Giuseppe Valenza; Silke Nickel; Yvonne Pfeifer; Christoph Eller; Elzbieta Krupa; Verena Lehner-Reindl; Christiane Höller
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.